Eris Lifesciences Limited has completed routine interest servicing on its outstanding Non-Convertible Debentures (NCDs) totaling ₹109.12 crore on June 8, 2026. The company fulfilled its obligations against two tranches of debt, each with an issue size of ₹625 crore, ensuring timely payments to debenture holders.

The payments were made in compliance with Regulation 57 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Milind Talegaonkar, Company Secretary & Compliance Officer, confirmed the completion of the transaction.

Interest Payment Details

The company serviced interest on two separate ISINs. The record date for both tranches was May 24, 2026, with the due date and actual payment date occurring on June 8, 2026. The frequency of interest payment for both instruments is annual.

Financial Breakdown

The total gross interest paid across both tranches amounted to ₹109.12 crore. After deducting Tax Deducted at Source (TDS), the net payout to holders was ₹105.99 crore.

There were no delays in payments, and no changes were reported in the frequency of interest servicing for these debentures.

Eris Lifesciences Limited has been penalised ₹4,24,800 each by BSE Limited and the National Stock Exchange of India Limited for non-compliance with board composition norms during the quarter ended March 31, 2026. The fines were imposed via letters dated May 27, 2026, following a violation of Regulation 17(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates specific requirements for the composition of the Board of Directors. The company clarified that the non-compliance occurred due to a board vacancy created by the completion of the term of an Independent Director. This vacancy has since been filled effective March 14, 2026, and the company stated that it is now in compliance with Regulation 17(1) of the SEBI Listing Regulations.

Details of the Penalty

The exchanges imposed the monetary penalty following the review of the company's board structure during the specified period. The company confirmed that there is no material impact on its financial or operational activities beyond the payment of the penalty amounts.

Eris Lifesciences affirmed its commitment to ensuring full compliance with all applicable laws and regulatory requirements moving forward. The disclosure was made in accordance with Regulation 30 of the SEBI Listing Regulations and the relevant SEBI master circular.